ReviewJournal of the American Academy of Dermatology2022
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
Review in Journal of the American Academy of Dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07767864 (A Single-arm Open-label Study Assessing Efficacy of Bimekizumab in Adult Participants With Pyoderma Gangrenosum Over 24 Weeks), which is not on this map. Cited by 104 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-arm Open-label Study Assessing Efficacy of Bimekizumab in Adult Participants With Pyoderma Gangrenosum Over 24 Weeks
Who cites it
104 citing papers in PubMed, 9 syntheses or guidelines pooled it, 203 citations in OpenAlex.
- Genomic loci and molecular genetic mechanisms for hidradenitis suppurativa.The British journal of dermatology · 2025Pooled it
- Australasian hidradenitis suppurativa management guidelines.The Australasian journal of dermatology · 2025Guideline
- Management of hidradenitis suppurativa in the inpatient setting: a clinical guide.Archives of dermatological research · 2025Guideline
- Relationship of vitamin D to pathogenesis and outcomes of hidradenitis suppurativa: a systematic review.Archives of dermatological research · 2024Pooled it
- Follicular Skin Disorders, Inflammatory Bowel Disease, and the Microbiome: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Hidradenitis suppurativa and its association with obesity, smoking, and diabetes mellitus: A systematic review and meta-analysis.International wound journal · 2024Pooled it
- Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel.Dermatology (Basel, Switzerland) · 2024Guideline
- Risk of psoriasis in people with hidradenitis suppurativa: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Risk of liver dysfunction and non-alcoholic fatty liver diseases in people with hidradenitis suppurativa: A systematic review and meta-analysis of real-world evidences.Frontiers in immunology · 2022Pooled it
- Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.Nature medicine · 2026Trial
- Incidence of Deep Vein Thrombosis and Pulmonary Embolism in Patients with Hidradenitis Suppurativa.Dermatology and therapy · 2026Article
- Future Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers.Experimental dermatology · 2026Article
- Serum Asprosin Levels in Patients with Hidradenitis Suppurativa: A Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
- Advancing Our Understanding of Hidradenitis Suppurativa: A Comprehensive Guide for Clinicians Designed to Improve Therapeutic Outcomes for Patients-Part 1.The Journal of clinical and aesthetic dermatology · 2026Review
- Patient-Level Risk Characterization of Drug-Associated Hidradenitis Suppurativa Using Machine Learning.medRxiv : the preprint server for health sciences · 2026Article
- Criteria for Hidradenitis Suppurativa Competence Centers.Dermatology and therapy · 2026Article
- Addictions in Hidradenitis Suppurativa: A Cross-Sectional Pilot Study.Dermatology and therapy · 2026Article
- Understanding Social Drivers of Health, Burden, and Impact of Hidradenitis Suppurativa among Different Racial and Ethnic Groups in the USA.Dermatology and therapy · 2026Article
- Joint pain and hidradenitis suppurativa: a retrospective cohort study.Skin health and disease · 2026Article
- A phenotype-to-mechanism framework links phenome-wide comorbidity architecture to molecular mechanisms and therapeutic discovery in complex diseases.medRxiv : the preprint server for health sciences · 2026Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 18 institutions in 2 countries.
Funding
Abstract
backgroundHidradenitis suppurativa (HS) is associated with comorbidities that contribute to poor health, impaired life quality, and mortality risk.
objectiveTo provide evidence-based screening recommendations for comorbidities linked to HS.
methodsSystematic reviews were performed to summarize evidence on the prevalence and incidence of 30 comorbidities in patients with HS relative to the general population. The screening recommendation for each comorbidity was informed by the consistency and quality of existing studies, disease prevalence, and magnitude of association, as well as benefits, harms, and feasibility of screening. The level of evidence and strength of corresponding screening recommendation were graded by using the Strength of Recommendation Taxonomy (SORT) criteria.
resultsScreening is recommended for the following comorbidities: acne, dissecting cellulitis of the scalp, pilonidal disease, pyoderma gangrenosum, depression, generalized anxiety disorder, suicide, smoking, substance use disorder, polycystic ovary syndrome, obesity, dyslipidemia, diabetes mellitus, metabolic syndrome, hypertension, cardiovascular disease, inflammatory bowel disease, spondyloarthritis, and sexual dysfunction. It is also recommended to screen patients with Down syndrome for HS. The decision to screen for specific comorbidities may vary with patient risk factors. The role of the dermatologist in screening varies according to comorbidity. LIMITATIONS: Screening recommendations represent one component of a comprehensive care strategy.
conclusionsDermatologists should support screening efforts to identify comorbid conditions in HS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.